Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Citius Oncology Logo
Citius Oncology Growth Score
89
CB Rank
1557
Heat Score
82
Citius Oncology is a pharmaceutical company that provides the development and commercialization of innovative oncology therapies.
Founded
obfuscation
PublicPost-IPO Debt Cranford, New Jersey, United States1-10 citiusonc.com/overview/default.aspx
Medical
Oncology
Pharmaceutical
Overview

Citius Oncology
Total Funding
obfuscation
Growth Score
89
Heat Score
82

Total Funding
obfuscation
obfuscation
Post-IPO Debt raised
obfuscation
Growth Score89
-6 pts
in past quarter
Heat Score 82
1 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Citius Oncology

CB Rank
1557
Citius Oncology is a pharmaceutical company that provides the development and commercialization of innovative oncology therapies.
Founded
obfuscation
PublicPost-IPO Debt Cranford, New Jersey, United States1-10 citiusonc.com/overview/default.aspx
Medical
Oncology
Pharmaceutical

Funding Rounds

Post-IPO Debt
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Details

Legal Name Citius Oncology, Inc.
Also Known As TrailOne
Operating Status Active
Stock Symbol  NASDAQ:CTOR
Company Type For Profit
About the Company
Citius Oncology is a biopharmaceutical company that develops and commercializes oncology therapies. The company specializes in targeted therapies for cancer treatment, with a focus on immune-based approaches. The company recently gained FDA approval for LYMPHIR™, a therapy for relapsed or refractory cutaneous T-cell lymphoma.
Phone Number +1 908-967-6677
Contact Email info@citiusonc.com
Predictions & Insights

Growth Insight

See this Growth Insight
Citius Oncology is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

LYMPHIR™ (denileukin diftitox-cxdl)
A targeted immune therapy approved for treating relapsed or refractory cutaneous T-cell lymphoma (CTCL).
LYMPHIR
LYMPHIR is a denileukin diftitox-cxdl immune therapy for adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma after prior systemic therapy.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 5
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Debt - Citius Oncology Logo
Post-IPO Debt - Citius Oncology
1
obfuscation
Avenue Capital GroupPost-IPO Debt
obfuscation
Post-IPO Debt - Citius Oncology Logo
Post-IPO Debt - Citius Oncology
1
obfuscation
Avenue Capital GroupPost-IPO Debt
obfuscation
Post-IPO Debt - Citius Oncology Logo
Post-IPO Debt - Citius Oncology
1
obfuscation
Avenue Capital GroupPost-IPO Debt
obfuscation
Post-IPO Debt - Citius Oncology Logo
Post-IPO Debt - Citius Oncology
1
obfuscation
Avenue Capital GroupPost-IPO Debt
obfuscation
Post-IPO Debt - Citius Oncology Logo
Post-IPO Debt - Citius Oncology
1
obfuscation
Avenue Capital GroupPost-IPO Debt

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 5
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Debt - Citius Oncology Logo
Post-IPO Debt - Citius Oncology
1
obfuscation
Avenue Capital GroupPost-IPO Debt
obfuscation
Post-IPO Debt - Citius Oncology Logo
Post-IPO Debt - Citius Oncology
1
obfuscation
Avenue Capital GroupPost-IPO Debt
obfuscation
Post-IPO Debt - Citius Oncology Logo
Post-IPO Debt - Citius Oncology
1
obfuscation
Avenue Capital GroupPost-IPO Debt
obfuscation
Post-IPO Debt - Citius Oncology Logo
Post-IPO Debt - Citius Oncology
1
obfuscation
Avenue Capital GroupPost-IPO Debt
obfuscation
Post-IPO Debt - Citius Oncology Logo
Post-IPO Debt - Citius Oncology
1
obfuscation
Avenue Capital GroupPost-IPO Debt

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Avenue Capital Group Logo
Avenue Capital Group
Yes
Post-IPO Debt - Citius Oncology Logo
Post-IPO Debt - Citius Oncology
—
Avenue Capital Group Logo
Avenue Capital Group
Yes
Post-IPO Debt - Citius Oncology Logo
Post-IPO Debt - Citius Oncology
—
Avenue Capital Group Logo
Avenue Capital Group
Yes
Post-IPO Debt - Citius Oncology Logo
Post-IPO Debt - Citius Oncology
—
Avenue Capital Group Logo
Avenue Capital Group
Yes
Post-IPO Debt - Citius Oncology Logo
Post-IPO Debt - Citius Oncology
—
Avenue Capital Group Logo
Avenue Capital Group
Yes
Post-IPO Debt - Citius Oncology Logo
Post-IPO Debt - Citius Oncology
—

Investments

Number of Acquisitions 1

Investment Breakdown

Number of Acquisitions 1
Market Intelligence
People
View Profiles & Contacts
Headcount 1-10
News

News and Press

News•Jun 1, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 1, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 1, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 26, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

1,100
171.6%
 in past month

Active Website Tech Count

8Citius Oncology is actively using 8 technologies for its website, according to BuiltWith. These include CommonCrawl Top 50m, Google Analytics, and  Global Site Tag.
Sub-Organizations
Frequently Asked Questions

Where is Citius Oncology's headquarters? Citius Oncology is located in Cranford, New Jersey, United States.Who invested in Citius Oncology? Citius Oncology is funded by Avenue Capital Group.When was the last funding round for Citius Oncology? Citius Oncology closed its last funding round on
obfuscation
from a Post-IPO Debt round.Who are Citius Oncology's competitors? Alternatives and possible competitors to Citius Oncology may include Avenzo Therapeutics, Tango Therapeutics, and  OS Therapies.How much funding has Citius Oncology raised to date? Citius Oncology has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(ccb7a32 1)
|